Skip to main content
. 2022 Feb 11;2022:8457010. doi: 10.1155/2022/8457010

Figure 5.

Figure 5

Schematic diagram of the role of glibenclamide on NLRP3 inflammasome in the pathogenesis of LPS-induced ALI. Glibenclamide blocked the activation of NLRP3 inflammasome induced by LPS and thus reduced the release of proinflammatory cytokines and then attenuated the lung injury consequently.